Eli Lilly buys psychedelics maker AtaiBeckley for $2.8 billion

Pharmaceutical giant Eli Lilly has announced a $2.8 billion deal to acquire AtaiBeckley, a maker of experimental psychedelic-based treatments. The acquisition gives Lilly access to drugs based on DMT and MDMA, which are gaining traction as potential treatments for mental health disorders. The move reflects growing pharmaceutical industry interest in psychedelic therapies.

Similar stories

🏥 Health Eli Lilly acquires psychedelic drug maker AtaiBeckley to expand mental health treatments CNBC · 25d ago 🏥 Health Psilocybin puts most veterans' PTSD into remission in breakthrough study The Independent World · 14d ago 🪖 Military US sailors show mental strain from Iran war deployment in the Middle East Vox · 4h ago